Clinical Trial Update: Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluates the combination of dacomitinib and PD-0325901 in advanced KRAS-mutant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dacomitinib (dacomitinib)
• PD-0325901 (PD-0325901)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED